These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 35450049)

  • 1. Rifaximin Ameliorates Non-alcoholic Steatohepatitis in Mice Through Regulating gut Microbiome-Related Bile Acids.
    Jian J; Nie MT; Xiang B; Qian H; Yin C; Zhang X; Zhang M; Zhu X; Xie WF
    Front Pharmacol; 2022; 13():841132. PubMed ID: 35450049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soyasaponin A
    Xiong F; Zheng Z; Xiao L; Su C; Chen J; Gu X; Tang J; Zhao Y; Luo H; Zha L
    Mol Nutr Food Res; 2021 Jul; 65(14):e2100067. PubMed ID: 34047448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rifaximin alleviates MCD diet-induced NASH in mice by restoring the gut microbiota and intestinal barrier.
    Shu YY; Hu LL; Ye J; Yang L; Jin Y
    Life Sci; 2024 Nov; 357():123095. PubMed ID: 39368771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gut Microbiota Plays Essential Roles in Soyasaponin's Preventive Bioactivities against Steatohepatitis in the Methionine and Choline Deficient (MCD) Diet-Induced Non-Alcoholic Steatohepatitis (NASH) Mice.
    Su C; Wang J; Luo H; Chen J; Lin F; Mo J; Xiong F; Zha L
    Mol Nutr Food Res; 2024 Feb; 68(4):e2300561. PubMed ID: 38234006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic alterations in the gut microbiota and metabolome during the development of methionine-choline-deficient diet-induced nonalcoholic steatohepatitis.
    Ye JZ; Li YT; Wu WR; Shi D; Fang DQ; Yang LY; Bian XY; Wu JJ; Wang Q; Jiang XW; Peng CG; Ye WC; Xia PC; Li LJ
    World J Gastroenterol; 2018 Jun; 24(23):2468-2481. PubMed ID: 29930468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Butyrate Protects Mice Against Methionine-Choline-Deficient Diet-Induced Non-alcoholic Steatohepatitis by Improving Gut Barrier Function, Attenuating Inflammation and Reducing Endotoxin Levels.
    Ye J; Lv L; Wu W; Li Y; Shi D; Fang D; Guo F; Jiang H; Yan R; Ye W; Li L
    Front Microbiol; 2018; 9():1967. PubMed ID: 30186272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elobixibat, an ileal bile acid transporter inhibitor, ameliorates non-alcoholic steatohepatitis in mice.
    Yamauchi R; Takedatsu H; Yokoyama K; Yamauchi E; Kawashima M; Nagata T; Uchida Y; Kitaguchi T; Higashi T; Fukuda H; Tsuchiya N; Takata K; Tanaka T; Morihara D; Takeyama Y; Shakado S; Sakisaka S; Hirai F
    Hepatol Int; 2021 Apr; 15(2):392-404. PubMed ID: 33398776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic potential of puerarin against methionine-choline-deficient diet-induced non-alcoholic steatohepatitis determined by combination of
    Gong MJ; Zhu CY; Zou ZJ; Han B; Huang P
    J Pharm Biomed Anal; 2021 Apr; 197():113964. PubMed ID: 33601157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bile acids override steatosis in farnesoid X receptor deficient mice in a model of non-alcoholic steatohepatitis.
    Wu W; Liu X; Peng X; Xue R; Ji L; Shen X; Chen S; Gu J; Zhang S
    Biochem Biophys Res Commun; 2014 May; 448(1):50-5. PubMed ID: 24747563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ursodeoxycholic Acid Treatment Restores Gut Microbiota and Alleviates Liver Inflammation in Non-Alcoholic Steatohepatitic Mouse Model.
    Li H; Wang Q; Chen P; Zhou C; Zhang X; Chen L
    Front Pharmacol; 2021; 12():788558. PubMed ID: 34938193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bile acids contribute to the development of non-alcoholic steatohepatitis in mice.
    Gillard J; Clerbaux LA; Nachit M; Sempoux C; Staels B; Bindels LB; Tailleux A; Leclercq IA
    JHEP Rep; 2022 Jan; 4(1):100387. PubMed ID: 34825156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Host ALDH2 deficiency aggravates nonalcoholic steatohepatitis through gut-liver axis.
    Li ZM; Kong CY; Mao YQ; Chen HL; Zhang SL; Huang JT; Yao JQ; Cai PR; Xie N; Han B; Wang LS
    Pharmacol Res; 2023 Oct; 196():106902. PubMed ID: 37657657
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Yang AM; Lin CY; Liu SH; Syu GD; Sun HJ; Lee KC; Lin HC; Hou MC
    Front Microbiol; 2022; 13():887728. PubMed ID: 35814685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intestinal Microbiota Protects against MCD Diet-Induced Steatohepatitis.
    Schneider KM; Mohs A; Kilic K; Candels LS; Elfers C; Bennek E; Schneider LB; Heymann F; Gassler N; Penders J; Trautwein C
    Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30646522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pegbelfermin selectively reduces secondary bile acid concentrations in patients with non-alcoholic steatohepatitis.
    Luo Y; Decato BE; Charles ED; Shevell DE; McNaney C; Shipkova P; Apfel A; Tirucherai GS; Sanyal AJ
    JHEP Rep; 2022 Jan; 4(1):100392. PubMed ID: 34977519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dihydromyricetin ameliorated nonalcoholic steatohepatitis in mice by regulating the composition of serous lipids, bile acids and ileal microflora.
    Miao X; Luo P; Liu J; Wang J; Chen Y
    Lipids Health Dis; 2023 Aug; 22(1):112. PubMed ID: 37533083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Honokiol affects the composition of gut microbiota and the metabolism of lipid and bile acid in methionine-choline deficiency diet-induced NASH mice.
    Zhai T; Wang J; Chen Y
    Sci Rep; 2023 Sep; 13(1):15203. PubMed ID: 37709801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice.
    Xu B; Jiang M; Chu Y; Wang W; Chen D; Li X; Zhang Z; Zhang D; Fan D; Nie Y; Shao F; Wu K; Liang J
    J Hepatol; 2018 Apr; 68(4):773-782. PubMed ID: 29273476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beneficial effects of silibinin on serum lipids, bile acids, and gut microbiota in methionine-choline-deficient diet-induced mice.
    Wang W; Zhai T; Luo P; Miao X; Wang J; Chen Y
    Front Nutr; 2023; 10():1257158. PubMed ID: 37867498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rifaximin and lubiprostone mitigate liver fibrosis development by repairing gut barrier function in diet-induced rat steatohepatitis.
    Enomoto M; Kaji K; Nishimura N; Fujimoto Y; Murata K; Takeda S; Tsuji Y; Fujinaga Y; Takaya H; Kawaratani H; Namisaki T; Akahane T; Yoshiji H
    Dig Liver Dis; 2022 Oct; 54(10):1392-1402. PubMed ID: 35514019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.